On Monday, Shares of Nokia Corp (ADR) (NYSE:NOK), subtract -2.49% and closed at $4.31 in the last trading session. The last trading range of the stock ranges between $4.28 and $4.33. The company’s Market capitalization is $24.59 Billion with the total Outstanding Shares of 5.77 billion. During the 52-week trading session the minimum price at which share price traded, registered at $4.28 and reached to max level of $7.55. The EPS of company is strolling at -0.13. Nokia Corporation
Stock Exchange Release
November 15, 2016 at 09:05 (CET +1)
Nokia Corporation to repurchase own shares in line with its capital structure optimization program
Espoo, Finland – In line with the EUR 7 billion capital structure optimization program declared earlier, the Nokia Board of Directors has resolved to begin a share repurchase program (the “Program”) under the authorization granted by the Nokia Annual General Meeting on June 16, 2016 (the “AGM”).
The Board has resolved to repurchase a maximum of 575 million Nokia shares up to an equivalent of EUR 1 billion.
The shares may be repurchased by way of a directed repurchase from sellers in marketplaces where the rules allow companies to trade with their own shares. The purchase price will be based on the current market price of Nokia shares in such marketplaces. The volumes to be repurchased may not exceed 25% of the daily average volume of the shares on the marketplace where the purchase is carried out. The daily average volume is based on the daily average volume traded during the month preceding the month of this disclosure.
Shares of Pfizer Inc.(NYSE:PFE), dropped -0.64% and closed at $32.38 in the last trading session. The last trading range of the stock ranges between $32.13 and $32.90. The company’s Market capitalization is $191.21 Billion with the total Outstanding Shares of 6.07 billion. During the 52-week trading session the minimum price at which share price traded, registered at $28.25 and reached to max level of $37.39. The EPS of company is strolling at 1.00. Pfizer Inc. (PFE) recently declared the pricing of a debt offering consisting of five tranches of notes:
$1,000,000,000 aggregate principal amount of 1.700% notes due 2019
$1,000,000,000 aggregate principal amount of 2.200% notes due 2021
$1,750,000,000 aggregate principal amount of 3.000% notes due 2026
$1,000,000,000 aggregate principal amount of 4.000% notes due 2036
$1,250,000,000 aggregate principal amount of 4.125% notes due 2046
Pfizer intends to use the net offering proceeds to fund the purchase of its 6.200% Senior Notes due March 15, 2019 (the “Tender Notes”) validly tendered and accepted for payment in Pfizer’s formerly declared tender offer (the “Tender Offer”) and to fund the redemption of any of the Tender Notes that remain outstanding after the completion of the Tender Offer in accordance with the terms of the make-whole provisions of the indenture governing the Tender Notes. Pfizer intends to use the remaining proceeds for general corporate purposes, counting to refinance, redeem or repurchase existing debt and to repay a portion of its outstanding commercial paper.